Program
rondecabtagene autoleucel
Also written as “Rondecabtagene autoleucel (ronde-cel)”.
Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Lymphoma, B-Cell, led by Lyell Immunopharma.
Furthest: phase 3, since Sep 16, 20252 company-led studies, 2 open or runningNext primary completion: Dec 31, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lyell Immunopharma | 22 open or running | phase 3since Sep 16, 2025 | Mar 24, 2023 | Dec 31, 2028phase 2 · NCT05826535 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2023First study: phase 2 study in Lymphoma, Non-HodgkinFirst studyNCT05826535 · 270 planned · United States, Australia
- Sep 16, 2025Phase 3 study in Lymphoma, B-CellNCT07188558 · 400 planned · United States, Australia, Canada
Ahead
- Dec 31, 2028Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT05826535
- Dec 2029Primary completion: phase 3 study in Lymphoma, B-CellNCT07188558
TargetBeta
“A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
| Autologous Anti-CD19/CD20 CAR-T Cells KITE-363rule | Gilead Sciences | phase 2 | 3 |
| prizloncabtagene autoleucelrule | AbelZeta | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203rule | avencell-therapeutics-inc | phase 2 | 1 |
| CT204V-CD19 × CD20rule | AstraZeneca | phase 2 | 1 |
| HB2198rule | hinge-bio | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07188558Lymphoma, B-Cell · United States, Australia, Canada | 3 | Recruiting | Dec 2029 | 400 |
| NCT05826535Lymphoma, Non-Hodgkin · United States, Australia | 2 | Recruiting | Dec 31, 2028 | 270 |
How it is read
Names in the registry
- “rondecabtagene autoleucel”, 1 entry
- “Rondecabtagene autoleucel (ronde-cel)”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 1 study
- Lymphoma, B-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.